ALTHX.PA
Theranexus Société Anonyme [ALTHX.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALTHX.PA Stock Summary
Top 10 Correlated ETFs
ALTHX.PA
Top 10 Correlated Stocks
ALTHX.PA
In the News
ALTHX.PA Financial details
Company Rating
-
Market Cap
8.78M
Income
-14.64M
Revenue
658.01K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
19
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-1.01
Forward P/E
-
PEG
-0.16
P/S
-
P/B
1.02
P/C
-
P/FCF
-1.56
Quick Ratio
6.34
Current Ratio
7.33
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.72
EPS next Y
-
EPS next Q
-
EPS this Y
-25.3%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-6.12%
Revenue last 5Y
30.19%
Revenue Q/Q
10783.34%
EPS Q/Q
11.48%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-48%
ROE
-73%
ROC
-0.59%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.63-3.18
52W High
-
52W Low
-
RSI
60
Rel Volume
1.12
Avg Volume
36.23K
Volume
40.73K
Perf Week
9.89%
Perf Month
154.13%
Perf Quarter
108.33%
Perf Half Y
100%
-
-
-
-
Beta
2.354
-
-
Volatility
0.03%, 0.34%
Prev Close
0%
Price
1
Change
-1.96%
Company Profile
- Volume Average 36.23K
- Market Capitalization 8.78M
- Employee 19
- CEO Mr. Mathieu Charvériat
- Headquarters Lyon,FR
- IPO Date 2017-10-30
-
Website
https://www.theranexus.com 
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
